Bevacizumab
- PDF / 169,509 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 92 Downloads / 229 Views
1 S
Incomplete third nerve palsy with pupillary involvement: case report An 85-year-old woman developed incomplete third nerve palsy with pupillary involvement during treatment with bevacizumab for neovascular age-related macular degeneration (NVAMD). The woman, who had mild hypertension and NVAMD, started receiving treatment with intravitreal bevacizumab injection [dosage not stated]. After the fourth bevacizumab injection (administered 3 weeks before presentation), she presented to the emergency room with double vision and dizziness. On examination, she had a profound reduction in adduction and elevation. She also showed mild light reactive mydriasis and ptosis in the left eye. Angio and brain MRI scan did not show evidence of infarction of any pertinent abnormalities of the major cerebral vessels. On the basis of these results, she was diagnosed with vasculopathic form of oculomotor nerve palsy (third nerve palsy) by occlusion of the small penetrating arteries secondary to the antiangiogenic bevacizumab therapy [outcome not stated]. Perez Trapote F, et al. Incomplete third nerve palsy with pupillary involvement following intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: Case report and literature review. European Journal of Neurology 27 (Suppl. 1): 740-741 (plus poster) abstr. EPO1344, May 2020. Available from: URL: https:// 803498487 onlinelibrary.wiley.com/doi/epdf/10.1111/ene.14308 [abstract]
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
